Eyepoint Pharmaceuticals, INC Form 4 insider transactions

Jay S. Duker, President and CEO and a Director of EyePoint Pharmaceuticals, Inc., reported multiple transactions in common stock on July 10, 2026.

Ramiro Ribeiro, Chief Medical Officer of EyePoint, Inc., reported transactions involving the acquisition and disposition of company common stock and stock options on June 30, 2026.

EyePoint, Inc. Chief Financial Officer George Elston reported transactions involving common stock and restricted stock units, including shares withheld for tax purposes.

Chief Medical Officer Ramiro Ribeiro exercised options for 2,437 shares of EyePoint, Inc. and subsequently sold them.

EyePoint, Inc. President and CEO Jay S. Duker transferred common stock and stock options valued at over $2.3 million to a family trust for estate planning purposes.

EyePoint, Inc. President and CEO Jay S. Duker reported a planned indirect acquisition of 1,500 common shares at $13.1492, effective March 16, 2026, under a 10b5-1 plan.

EyePoint Inc.'s Chief Financial Officer, George Elston, transferred 5,000 shares of common stock to an irrevocable family trust.

EyePoint's Chief Medical Officer, Ramiro Ribeiro, exercised stock options and subsequently sold 2,438 shares of common stock.

EyePoint, Inc. Director Nancy Lurker converted 75,133 restricted stock units into common stock, increasing her direct beneficial ownership.

EyePoint, Inc. President and CEO Jay S. Duker reported the vesting of restricted stock units and subsequent tax-related share withholding.

EyePoint, Inc.'s Chief Financial Officer, George Elston, reported the vesting of 15,285 restricted stock units and the subsequent sale of 4,487 shares for tax withholding purposes.

EyePoint, Inc.'s Chief Medical Officer, Ramiro Ribeiro, exercised stock options and subsequently sold a significant number of common shares.

EyePoint, Inc.'s Chief Medical Officer, Ramiro Ribeiro, reported the acquisition of new restricted stock units and stock options, alongside a tax-related disposition of shares.

EyePoint, Inc. President and CEO Jay S. Duker reported the acquisition of new restricted stock units and stock options, alongside common stock acquisitions and tax-related dispositions.

EyePoint, Inc.'s Chief Financial Officer, George Elston, reported recent acquisitions of common stock and derivative securities, alongside dispositions for tax obligations.

EyePoint, Inc. Director Karen L. Zaderej acquired 40,000 stock options with an exercise price of $17.48, exercisable from January 2, 2027.

EyePoint, Inc. Director Reginald J. Sanders was granted 40,000 stock options with an exercise price of $17.48, exercisable from January 2, 2027.

EyePoint, Inc. Director Nancy Lurker reported the acquisition of 40,000 stock options and the vesting of 12,666 restricted stock units, converting to common stock.

EyePoint, Inc. Director John B. Landis acquired 40,000 stock options with an exercise price of $17.48, exercisable from January 2, 2027.

EyePoint, Inc. Director Stuart Duty was granted 40,000 stock options with an exercise price of $17.48, exercisable from January 2, 2027.

EyePoint, Inc. Director Fred Hassan was granted 40,000 stock options with an exercise price of $17.48, exercisable from January 2, 2027.

EyePoint, Inc. Director Wendy F. DiCicco was granted 40,000 stock options with an exercise price of $17.48, exercisable from January 2, 2027.

EyePoint, Inc. Director Goran Ando reported the acquisition of 41,500 stock options with an exercise price of $17.48.

EyePoint, Inc. Chief Financial Officer George Elston transferred 5,000 shares of common stock to an irrevocable family trust.

Cormorant Asset Management and related entities reported the sale of 60,000 shares of EyePoint, Inc. common stock at a weighted average price of $15.704 per share.

EyePoint Pharmaceuticals Director Nancy Lurker sold 9,300 shares of common stock for a weighted average price of $15.1051 per share.

EyePoint Pharmaceuticals Director Nancy Lurker sold 700 shares of common stock for $14.95 per share under a pre-arranged 10b5-1 plan.

EyePoint Pharmaceuticals' Chief Medical Officer, Ramiro Ribeiro, sold 2,722 shares of common stock for approximately $31,595 under a pre-arranged trading plan.

EyePoint Pharmaceuticals' Chief Financial Officer, George Elston, transferred 20,000 shares of common stock to an irrevocable family trust.

EyePoint Pharmaceuticals Director Karen L. Zaderej acquired 2,000 shares of common stock through the conversion of restricted stock units on July 11, 2025, increasing her direct beneficial ownership to 38,500 shares.